 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | NM21-1480 / Numab
Enrollment change, Trial termination, Trial primary completion date, Trispecific, Metastases: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 28, 2024
P1/2, N=52, Terminated, Sponsor: Numab Therapeutics AG
N=406 --> 52 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Feb 2024; A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
- || NM21-1480 / Numab
Trial completion date, Trispecific, Metastases: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 31, 2023
P1/2, N=406, Active, not recruiting, Sponsor: Numab Therapeutics AG
- ||| NM21-1480 / Numab
Enrollment closed, Trispecific, Metastases: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Nov 20, 2023
P1/2, N=406, Active, not recruiting, Sponsor: Numab Therapeutics AG
There were no safety concerns that contributed to this decision. Recruiting --> Active, not recruiting
- | NM21-1480 / Numab, NM28-2746 / Numab
Journal, PD(L)-1 Biomarker, IO biomarker: An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin. (Pubmed Central) - Jul 21, 2023
In xenograft models, NM28-2746 exhibited significant tumor suppressing activity, which was significantly enhanced by combination therapy with NM21-1480. NM28-2746, alone or in combination with NM21-1480, may overcome shortcomings of previous MSLN-targeted immuno-oncology drugs, exhibiting enhanced discrimination of high MSLN-expressing cell activity in the presence of sMSLN.
- ||| NM21-1480 / Numab
Enrollment change, Trial completion date, Trial primary completion date, Trispecific, Metastases: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 17, 2023
P1/2, N=406, Recruiting, Sponsor: Numab Therapeutics AG
NM28-2746, alone or in combination with NM21-1480, may overcome shortcomings of previous MSLN-targeted immuno-oncology drugs, exhibiting enhanced discrimination of high MSLN-expressing cell activity in the presence of sMSLN. N=147 --> 406 | Trial completion date: Jun 2023 --> Jan 2025 | Trial primary completion date: Jan 2023 --> Jan 2024
- NM21-1480 / Numab
First-in-human trial to evaluate safety, PK/PD and initial clinical activity of NM21-1480, an affinity-balanced PD-L1x4-1BBxHSA trispecific antibody: Results of Phase 1 dose escalation (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1049;
Encouraging early clinical activity across different dose levels was observed in a heavily pretreated population with advanced solid tumors, including those resistant to prior immunotherapy or typically less sensitive to ICIs. Enrollment into expansion cohorts will start in the second half of 2022.
- | Bavencio (avelumab) / EMD Serono, Pfizer, NM21-1480 / Numab
Journal: Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade. (Pubmed Central) - Jul 20, 2022
A GLP toxicology study revealed no evidence of liver toxicity at doses up to 140 mg/kg, and pharmacokinetic studies in non-human primates suggested a plasma half-life in humans of up to 2 weeks. NM21-1480 has the potential to overcome checkpoint resistance by co-activating tumor-infiltrating lymphocytes without liver toxicity.
- NM28-2746 / Numab
NM28-2746, a reduced affinity bivalent mesothelin-binding MATCH4 T cell engager, with half-life extension, increases selectivity for killing of mesothelin-overexpressing cells (Section 37) - Mar 9, 2022 - Abstract #AACR2022AACR_4805;
Collectively, these data demonstrate an increased selectivity to mesothelin-overexpressing cells by this novel MATCH4 reduced affinity bivalent T cell engager. These data indicate the potential of this molecule to increase the therapeutic window by reducing safety concerns on normal tissue where mesothelin expression is low, and yet promote cytotoxicity on mesothelin over-expressing cancer cells.
- NM21-1480 / Numab
Dose selection investigations and combination strategies of NM21-1480, a PD-L1/4-1BB/HSA trispecific MATCH3 therapeutic clinical candidate (Section 37) - Mar 9, 2022 - Abstract #AACR2022AACR_4804;
In particular, we demonstrate that the combination of NM21-1480 with anti-CD3 T cell engagers is highly effective in T cell activation and tumor control. These data highlight the potential of NM21-1480 for the treatment of cancer patients and enable greater understanding of the relationship between dose, tumor exposure, immune activation and tumor growth inhibition.
- ||| NM21-1480 / Numab
#CStone received China #NMPA #IND approval for #CS2006/#NM211480, a #PDL1/#41BB/#HSA #multispecificantibody-based molecule, marking further expansion of its Pipeline 2.0 https://t.co/rCi5EqcK23 (Twitter) - Sep 19, 2021
- ||| NM21-1480 / Numab
Enrollment change, Trial completion date, Trial primary completion date, IO biomarker, Trispecific, Metastases: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 19, 2021
P1/2, N=147, Recruiting, Sponsor: Numab Therapeutics AG
These data highlight the potential of NM21-1480 for the treatment of cancer patients and enable greater understanding of the relationship between dose, tumor exposure, immune activation and tumor growth inhibition. N=102 --> 147 | Trial completion date: Aug 2022 --> Jun 2023 | Trial primary completion date: Jul 2022 --> Jan 2023
- NM21-1480 / Numab
[VIRTUAL] Multispecific MATCHTM Antibodies – Design and Development of Next-Generation Cancer Therapeutics () - Apr 4, 2021 - Abstract #PEGS2021PEGS_551;
Careful selection of format, epitopes and affinities resulted in optimized activity and a favorable safety profile in non-human primates. Additional therapeutic approaches based on Numab’s MATCHTM platform are presented.
- NM21-1480 / Numab
[VIRTUAL] Multi-Specific MATCH Antibodies Enable Novel Therapeutic Strategies by Targeting Synergistic Immunomodulatory Functions to the Tumor Microenvironment () - Aug 18, 2020 - Abstract #IOS2020IOS_9;
NM21-1480 shows superior efficacy over conventional CPI therapies and avoids dose-limiting toxicities of systemic 4-1BB agonism. Further, tetra-specific MATCH4 molecules are exploited to improve on safety and efficacy of conventional bispecific strategies.
- ||| NM21-1480 / Numab
Enrollment open, IO biomarker, Trispecific, Metastases: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 6, 2020
P1/2, N=102, Recruiting, Sponsor: Numab Therapeutics AG
Further, tetra-specific MATCH4 molecules are exploited to improve on safety and efficacy of conventional bispecific strategies. Not yet recruiting --> Recruiting
- | NM21-1480 / Numab
New P1/2 trial, IO biomarker, Trispecific, Metastases: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 22, 2020
P1/2, N=102, Not yet recruiting, Sponsor: Numab Therapeutics AG
- NM21-1480 / Numab
Preclinical development and mechanism of action studies of NM21-1480, a PD-L1/4-1BB/HSA trispecific MATCH3 therapeutic clinical candidate (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1465;
We report on the toxicity profile and pharmacokinetic properties of the molecule in non-human primates. We plan to initiate a first-in-human clinical study in the second half of 2020 to determine the safety, tolerability and first signs of clinical activity of the molecule.